Understanding how kappa opioid receptors work to improve pain management and reduce addiction risks
Official title: Mechanisms and Regulations of kappa Opioid Receptor Signaling
Funded at Washington University · NIH-11111366 · Data updated 2026-11-12
This study is looking at a special receptor in the body that could help manage pain and treat addiction in a safer way than traditional opioids, so patients can find relief without the harsh side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | June 15, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $454,994 |
| NIH project number | 5R01DA058020-02 |
| Project ID | NIH-11111366 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from chronic pain or addiction disorders who are seeking alternative treatment options.
✕Less likely to help
Patients who do not experience pain or addiction issues may not receive any benefit from this research.
What this research studies
This research investigates the kappa opioid receptor (KOR) as a potential alternative for pain management and addiction treatment. By exploring the mechanisms and regulators that control KOR signaling, the study aims to identify new ways to alleviate pain without the severe side effects associated with traditional opioids. The research involves detailed analysis of KOR interactions with various G proteins and β-arrestins, which are crucial for understanding how these receptors can be effectively targeted for therapeutic benefits. Patients may benefit from new treatment options that are safer and less addictive than current opioid medications.
Why it matters
Potential benefit: If successful, this research could lead to safer pain management options that reduce the risk of addiction and overdose.
How similar studies have gone: Previous research has shown promise in targeting kappa opioid receptors for pain relief and addiction treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Che, Tao — Washington University
- Study coordinator: Che, Tao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.